(Circulation. 1999;100:869-875.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Aminorex, Fenfluramine, and Chlorphentermine Are Serotonin Transporter Substrates
Implications for Primary Pulmonary Hypertension
From the Clinical Psychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Md.
Correspondence to Richard B. Rothman, MD, PhD, Clinical Psychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 5500 Nathan Shock Dr, PO Box 5180, Baltimore, MD 21224. E-mail rrothman{at}intra.nida.nih.gov
Background—Coadministration of phentermine and fenfluramine (phen/fen) effectively treats obesity and possibly addictive disorders. The association of fenfluramine and certain other anorexic agents with serious side effects, such as cardiac valvulopathy and primary pulmonary hypertension (PPH), limits the clinical utility of these drugs. Development of new medications that produce neurochemical effects like phen/fen without causing unwanted side effects would be a significant therapeutic breakthrough.
Methods and Results—We tested the hypothesis that fenfluramine (and other anorexic agents) might increase the risk of PPH through interactions with serotonin (5-HT) transporters. Because 5-HT transporter proteins in the lung and brain are identical, we examined, in rat brain, the effects of selected drugs on 5-HT efflux in vivo and monoamine transporters in vitro as a generalized index of transporter function. Our data show that drugs known or suspected to increase the risk of PPH (eg, aminorex, fenfluramine, and chlorphentermine) are 5-HT transporter substrates, whereas drugs that have not been shown to increase the risk of PPH are less potent in this regard.
Conclusions—We speculate that medications that are 5-HT transporter substrates get translocated into pulmonary cells where, depending on the degree of drug retention, their intrinsic drug toxicity, and individual susceptibility, PPH could develop as a response to high levels of these drugs or metabolites. Emerging evidence suggests that it is possible to develop transporter substrates devoid of adverse side effects. Such medications could have therapeutic application in the management of obesity, drug dependence, depression, and other disorders.
Key Words: pulmonary heart disease • hypertension • drugs • obesity
This article has been cited by other articles:
 |
|
 |
|
  L. Kugathasan, J. B. Ray, Y. Deng, E. Rezaei, D. J. Dumont, and D. J. Stewart The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice J. Exp. Med., September 28, 2009; 206(10): 2221 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu and B. L. Fanburg Phospholipase D signaling in serotonin-induced mitogenesis of pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L471 - L478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dempsie, I. Morecroft, D. J. Welsh, N. A. MacRitchie, N. Herold, L. Loughlin, M. Nilsen, A. J. Peacock, A. Harmar, M. Bader, et al. Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice Circulation, June 3, 2008; 117(22): 2928 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Chin and L. J. Rubin Pulmonary arterial hypertension. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1527 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Weir, M. Obreztchikova, and Z. Hong Fenfluramine: riddle or Rosetta stone? Eur. Respir. J., February 1, 2008; 31(2): 232 - 235. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gopalakrishnan, M. Sievert, and A. E. Ruoho Identification of the Substrate Binding Region of Vesicular Monoamine Transporter-2 (VMAT-2) Using Iodoaminoflisopolol as a Novel Photoprobe Mol. Pharmacol., December 1, 2007; 72(6): 1567 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Rothman and M. H. Baumann Methamphetamine and Idiopathic Pulmonary Arterial Hypertension: Role of the Serotonin Transporter Chest, October 1, 2007; 132(4): 1412 - 1413. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Partilla, A. G. Dempsey, A. S. Nagpal, B. E. Blough, M. H. Baumann, and R. B. Rothman Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 237 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zolkowska, R. B. Rothman, and M. H. Baumann Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 604 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Willers, J. H. Newman, J. E. Loyd, I. M. Robbins, L. A. Wheeler, M. A. Prince, K. C. Stanton, J. A. Cogan, J. R. Runo, D. Byrne, et al. Serotonin Transporter Polymorphisms in Familial and Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 798 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rezaie-Majd, J. Murar, D. P. Nelson, R. F. Kelly, Z. Hong, I. M. Lang, A. Varghese, and E. K. Weir Increased release of serotonin from rat ileum due to dexfenfluramine Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1209 - R1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Marcos, S. Adnot, M. H. Pham, A. Nosjean, B. Raffestin, M. Hamon, and S. Eddahibi Serotonin Transporter Inhibitors Protect against Hypoxic Pulmonary Hypertension Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Rothman, R. D. Clark, J. S. Partilla, and M. H. Baumann (+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1191 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Suzuki, R. M. Day, C. C. Tan, T. H. Sandven, Q. Liang, J. D. Molkentin, and B. L. Fanburg Activation of GATA-4 by Serotonin in Pulmonary Artery Smooth Muscle Cells J. Biol. Chem., May 2, 2003; 278(19): 17525 - 17531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Belohlavkova, J. Simak, A. Kokesova, O. Hnilickova, and V. Hampl Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels J Appl Physiol, August 1, 2001; 91(2): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Nebigil, P. Hickel, N. Messaddeq, J.-L. Vonesch, M. P. Douchet, L. Monassier, K. Gyorgy, R. Matz, R. Andriantsitohaina, P. Manivet, et al. Ablation of Serotonin 5-HT2B Receptors in Mice Leads to Abnormal Cardiac Structure and Function Circulation, June 19, 2001; 103(24): 2973 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Baumann, R. B. Rothman, J. P. Pablo, and D. C. Mash In Vivo Neurobiological Effects of Ibogaine and Its O-Desmethyl Metabolite, 12-Hydroxyibogamine (Noribogaine), in Rats J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 531 - 539. [Abstract] [Full Text]
|
|
|
|
|
|
S. Eddahibi, S. Adnot, E. Frisdal, M. Levame, M. Hamon, and B. Raffestin Dexfenfluramine-Associated Changes in 5-Hydroxytryptamine Transporter Expression and Development of Hypoxic Pulmonary Hypertension in Rats J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 148 - 154. [Abstract] [Full Text]
|
|
|
|
|
|
S. Archer and S. Rich Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress" Circulation, November 28, 2000; 102(22): 2781 - 2791. [Abstract] [Full Text] [PDF]
|
|